The efficacy of Xialine®in patients with xerostomia resulting from radiotherapy for head and neck cancer: A pilot-study

Radiotherapy and Oncology

Volumn 59, Issue 2, 2001, Pages 157-160

  Jellema, Anke Petra ^a   Langendijk, Hans ^a   Bergenhenegouwen, Lester ^a   Van Der Reijden, Willy ^b   Leemans, Rene ^a   Smeele, Ludy ^a   Slotman, Berend J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Head and neck cancer; Irradiation; Quality of life; Saliva substitute; Xerostomia

Indexed keywords

PLACEBO; SALIVA SUBSTITUTE; UNCLASSIFIED DRUG; XANTHAN; XIALINE; BACTERIAL POLYSACCHARIDE;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEAD CANCER; HUMAN; MALE; NECK CANCER; PRIORITY JOURNAL; QUESTIONNAIRE; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; SENSATION; SENSORY DYSFUNCTION; SPEECH DISORDER; TREATMENT OUTCOME; XEROSTOMIA; CHI SQUARE DISTRIBUTION; HEAD AND NECK TUMOR; MIDDLE AGED; PILOT STUDY; RADIOTHERAPY;

AGED; CHI-SQUARE DISTRIBUTION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; POLYSACCHARIDES, BACTERIAL; QUESTIONNAIRES; RADIOTHERAPY; SALIVA, ARTIFICIAL; XEROSTOMIA;

EID: 0035324593     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(01)00336-X     Document Type: Article

References (22)

1. Aaronson N.K., Ahmedzai S., Bergman B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in the international clinical trials in oncology. J Natl Cancer Inst. 85:1993;365-376.
2. Bjordal K., Kaasa S. Psychometric validation of the EORTC Core Quality of Life Questionnaire, 30-item version and a diagnosis-specific module for head and neck cancer patients. Acta Oncol. 31:1992;311-332.
3. Bjordal K., Ahlner-Elmqvist M., Tollesson E., et al. Development of a European Organization for Research and Treatment of Cancer (EORTC) questionnaire module to be used in quality of life assessments in head and neck cancer patients: EORTC Quality of Life Study Group. Acta Oncol. 33:1994;879-885.
4. Bjordal K., Hammerlid E., Ahlner-Elmqist M., et al. Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Questionnaire-H&N35. J Clin Oncol. 3:(17):1999;1008-1019.
5. Björnström M., Axéll T., Birkhed D. Comparison between saliva stimulants and saliva substitutes in patients with symptoms related to dry mouth. Swed Dent J. 14:1990;153-161.
6. Davies A.N., Singer J. A comparison of artificial saliva and pilocarpine in radiation-induced xerostomia. J Laryngol Otol. 108:1994;663-665.
7. Dreizen S., Brown L.R., Handler S., Levy B.M. Radiation induced xerostomia in cancer patients. Effect on salivary and serum electrolytes. Cancer. 38:1976;273-278.
8. Dreizen S., Brown L.R., Daly T.E., et al. Prevention of xerostomia-related dental caries in irradiated cancer patients. J Dent Res. 56:1977;99-104.
9. Eisbruch A., Ten Haken R.K., Kim H.M., Marsh L.H., Ship J.A. Dose, volume and functional relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys. 45:(3):1999;577-587.
10. Fayers P., Aaronson N.K., Bjordal K. EORTC QLQ-C30 scoring manual. 1995;European Organization for Research and Treatment of Cancer, Brussels.
11. Fox P.C., Atkinson J.C., Macynski A.A., et al. Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia). Arch Intern Med. 151:1991;1149-1152.
12. Franzen L., Funegard U., Ericson T., Henriksson R. Parotid gland function during and following radiotherapy of malignancies in the head and neck. Eur J Cancer. 28:1992;457-462.
13. 's-Gravenmade E.J., Roukema P.A., Panders A.K. The effect of mucin-containing artificial saliva on severe xerostomia. Int J Oral Surg. 3:1974;435-439.
14. Jensen A.B., Hansen O., Jorgensen K., Bastholt L. Influence of late side effects upon daily life after radiotherapy for laryngeal and pharyngeal cancer. Acta Oncol. 33:1994;487-491.
15. Johnson J.T., Ferretti G.A., Nethery W.J., et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med. 329:1993;390-395.
16. Matzker J., Schreiber J. Synthetischer Speichel zur Therapie der Hyposalien, insbesondere bei der radiogenen Sialadenitis. Z Laryngol Rhinol Otol. 51:1972;422-428.
17. Roberts B.J. Help for the dry mouth patient. J Dent. 10:1982;226-234.
18. Van der Reijden W.A., Veerman E.C.I., van Nieuw Amerongen A. Rheological properties of commercially available polysaccharides with potential use in saliva substitutes. Biorheology. 31:1994;631-642.
19. Van der Reijden W.A., van der Kwaak H., Vissink A., Veerman E.C.I., van Nieuw Amerongen A. Treatment of xerostomia with polymer-based saliva substitutes in patients with Sjögren's syndrome. Arthr Rheumatol. 39:1996;57-63.
20. Van der Reijden W.A., Buijs M.J., Damen J.J.M., Veerman E.C.I., ten Cate J.M., van Nieuw Amerongen A. Influence of polymers for use in saliva substitutes on de- and remineralization of enamel in vitro. Caries Res. 31:1997;216-223.
21. Vissink A., 's-Gravenmade E.J., Panders A.K., Vermey A., Petersen J.K., Visch L.L. A clinical comparison between commercially available mucine- and CMC-containing saliva substitutes. J Oral Surg. 12:1983;232-238.
22. Vissink A., van Nieuw Amerongen A., Wesseling H., 's-Gravenmade E.J. De droge mond - de mogelijk oorzakelijke rol van geneesmiddelen. Nederlands Tijdschrift Tandheelkunde. 99:1992;103-107.